vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and PROSPERITY BANCSHARES INC (PB). Click either name above to swap in a different company.
PROSPERITY BANCSHARES INC is the larger business by last-quarter revenue ($367.6M vs $339.0M, roughly 1.1× HAEMONETICS CORP). PROSPERITY BANCSHARES INC runs the higher net margin — 31.6% vs 13.2%, a 18.4% gap on every dollar of revenue. Over the past eight quarters, PROSPERITY BANCSHARES INC's revenue compounded faster (19.2% CAGR vs 0.4%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
Prosperity Bancshares, Inc. is a bank holding company headquartered in Houston, Texas with operations in Texas and central Oklahoma. As of December 31, 2019, the company operated 285 branches: 65 in the Houston area, including The Woodlands, Texas; 30 in South Texas, including Corpus Christi, Texas and Victoria, Texas; 75 in the Dallas–Fort Worth metroplex; 22 in East Texas; 29 in Central Texas, including Austin, Texas and San Antonio; 34 in West Texas, including Lubbock, Texas, Midland–Odess...
HAE vs PB — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $339.0M | $367.6M |
| Net Profit | $44.7M | $116.3M |
| Gross Margin | 59.7% | — |
| Operating Margin | 19.9% | — |
| Net Margin | 13.2% | 31.6% |
| Revenue YoY | -2.7% | — |
| Net Profit YoY | 19.3% | -10.7% |
| EPS (diluted) | $0.95 | $1.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $367.6M | ||
| Q4 25 | $339.0M | $275.0M | ||
| Q3 25 | $327.3M | $273.4M | ||
| Q2 25 | $321.4M | $267.7M | ||
| Q1 25 | $330.6M | $265.4M | ||
| Q4 24 | $348.5M | $267.8M | ||
| Q3 24 | $345.5M | $261.7M | ||
| Q2 24 | $336.2M | $258.8M |
| Q1 26 | — | $116.3M | ||
| Q4 25 | $44.7M | $139.9M | ||
| Q3 25 | $38.7M | $137.6M | ||
| Q2 25 | $34.0M | $135.2M | ||
| Q1 25 | $58.0M | $130.2M | ||
| Q4 24 | $37.5M | $130.1M | ||
| Q3 24 | $33.8M | $127.3M | ||
| Q2 24 | $38.4M | $111.6M |
| Q1 26 | — | — | ||
| Q4 25 | 59.7% | — | ||
| Q3 25 | 59.5% | — | ||
| Q2 25 | 59.8% | — | ||
| Q1 25 | 58.4% | — | ||
| Q4 24 | 55.5% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 52.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | 19.9% | 65.1% | ||
| Q3 25 | 17.9% | 64.4% | ||
| Q2 25 | 16.8% | 64.3% | ||
| Q1 25 | 21.6% | 62.7% | ||
| Q4 24 | 16.9% | 62.0% | ||
| Q3 24 | 15.0% | 62.1% | ||
| Q2 24 | 11.8% | 55.2% |
| Q1 26 | — | 31.6% | ||
| Q4 25 | 13.2% | 50.9% | ||
| Q3 25 | 11.8% | 50.3% | ||
| Q2 25 | 10.6% | 50.5% | ||
| Q1 25 | 17.5% | 49.1% | ||
| Q4 24 | 10.8% | 48.6% | ||
| Q3 24 | 9.8% | 48.6% | ||
| Q2 24 | 11.4% | 43.1% |
| Q1 26 | — | $1.16 | ||
| Q4 25 | $0.95 | $1.48 | ||
| Q3 25 | $0.81 | $1.45 | ||
| Q2 25 | $0.70 | $1.42 | ||
| Q1 25 | $1.17 | $1.37 | ||
| Q4 24 | $0.74 | $1.36 | ||
| Q3 24 | $0.66 | $1.34 | ||
| Q2 24 | $0.74 | $1.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $363.4M | — |
| Total DebtLower is stronger | $1.2B | — |
| Stockholders' EquityBook value | $911.5M | $8.2B |
| Total Assets | $2.5B | $43.6B |
| Debt / EquityLower = less leverage | 1.34× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $363.4M | — | ||
| Q3 25 | $296.4M | — | ||
| Q2 25 | $292.9M | — | ||
| Q1 25 | $306.8M | — | ||
| Q4 24 | $320.8M | — | ||
| Q3 24 | $299.3M | — | ||
| Q2 24 | $344.4M | — |
| Q1 26 | — | — | ||
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $8.2B | ||
| Q4 25 | $911.5M | $7.6B | ||
| Q3 25 | $849.2M | $7.7B | ||
| Q2 25 | $882.3M | $7.6B | ||
| Q1 25 | $820.8M | $7.5B | ||
| Q4 24 | $906.9M | $7.4B | ||
| Q3 24 | $878.9M | $7.4B | ||
| Q2 24 | $905.4M | $7.3B |
| Q1 26 | — | $43.6B | ||
| Q4 25 | $2.5B | $38.5B | ||
| Q3 25 | $2.4B | $38.3B | ||
| Q2 25 | $2.5B | $38.4B | ||
| Q1 25 | $2.5B | $38.8B | ||
| Q4 24 | $2.5B | $39.6B | ||
| Q3 24 | $2.5B | $40.1B | ||
| Q2 24 | $2.5B | $39.8B |
| Q1 26 | — | — | ||
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.39× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $93.6M | — |
| Free Cash FlowOCF − Capex | $87.2M | — |
| FCF MarginFCF / Revenue | 25.7% | — |
| Capex IntensityCapex / Revenue | 1.9% | — |
| Cash ConversionOCF / Net Profit | 2.09× | — |
| TTM Free Cash FlowTrailing 4 quarters | $308.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $93.6M | $78.3M | ||
| Q3 25 | $111.3M | $194.8M | ||
| Q2 25 | $17.4M | $98.2M | ||
| Q1 25 | $116.6M | $178.2M | ||
| Q4 24 | $43.8M | $-205.8M | ||
| Q3 24 | $48.8M | $274.6M | ||
| Q2 24 | $-27.4M | $216.5M |
| Q1 26 | — | — | ||
| Q4 25 | $87.2M | $68.5M | ||
| Q3 25 | $106.3M | $185.7M | ||
| Q2 25 | $13.6M | $91.8M | ||
| Q1 25 | $100.9M | $171.1M | ||
| Q4 24 | $35.2M | $-210.7M | ||
| Q3 24 | $39.4M | $270.2M | ||
| Q2 24 | $-33.1M | $211.8M |
| Q1 26 | — | — | ||
| Q4 25 | 25.7% | 24.9% | ||
| Q3 25 | 32.5% | 67.9% | ||
| Q2 25 | 4.2% | 34.3% | ||
| Q1 25 | 30.5% | 64.5% | ||
| Q4 24 | 10.1% | -78.7% | ||
| Q3 24 | 11.4% | 103.3% | ||
| Q2 24 | -9.8% | 81.8% |
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | 3.6% | ||
| Q3 25 | 1.5% | 3.3% | ||
| Q2 25 | 1.2% | 2.4% | ||
| Q1 25 | 4.7% | 2.7% | ||
| Q4 24 | 2.5% | 1.8% | ||
| Q3 24 | 2.7% | 1.7% | ||
| Q2 24 | 1.7% | 1.8% |
| Q1 26 | — | — | ||
| Q4 25 | 2.09× | 0.56× | ||
| Q3 25 | 2.88× | 1.42× | ||
| Q2 25 | 0.51× | 0.73× | ||
| Q1 25 | 2.01× | 1.37× | ||
| Q4 24 | 1.17× | -1.58× | ||
| Q3 24 | 1.44× | 2.16× | ||
| Q2 24 | -0.71× | 1.94× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
PB
| Net Interest Income | $321.1M | 87% |
| Noninterest Income | $46.5M | 13% |
